Genetic and epigenetic changes contributing to leukemogenesis and prognostic impact in acute myeloid leukemia

Yueying Wang

DOI: https://doi.org/10.1016/j.exphem.2013.05.024

IF: 3.249

2013-01-01

Experimental Hematology

Abstract:Acute myeloid leukemia (AML) is a group of heterogeneous diseases. Abnormalities in genes that encode transcription factors and tyrosine kinases represent two classes of the most frequently detected genetic events in human AMLs. Recently, a new category of gene mutations associated with epigenetic regulation have also been proposed. Recurrent somatic mutations of DNMT3A were identified in 23 of 112 (20.5%) cases using exome sequencing technique. The DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. Gene expression profiles and DNA methylation patterns showed some differences between patients with and without DNMT3A mutations. Notably, we found that members of HOXB genes were extensively upregulated with mutations of DNMT3A, and hypomethylation of certain CpG islands in the HOXB locus. DNMT3A mutations enabled 32D cells to acquire growth and survival advantage with and without IL3. Leukemias with DNMT3A mutations constituted a group of poor prognosis with elderly disease onset. These data suggest a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocytic leukemia and provides a useful new biomarker for relevant cases. We performed the study to systemically investigate the frequencies and the prognostic relevance of previously known genetic events and newly established molecular markers in a large series of 1,185 adult AML patients. In particular, we intent to stratify the AML patients who lacked cytogenetic prognostic markers into appropriate prognostic groups. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event free survival (EFS), while bi-allelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in whole group and younger patients aged less than 60 years. Further studies will be focused on using different treatment strategies according to AML genotypes. Acute myeloid leukemia (AML) is a group of heterogeneous diseases. Abnormalities in genes that encode transcription factors and tyrosine kinases represent two classes of the most frequently detected genetic events in human AMLs. Recently, a new category of gene mutations associated with epigenetic regulation have also been proposed. Recurrent somatic mutations of DNMT3A were identified in 23 of 112 (20.5%) cases using exome sequencing technique. The DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. Gene expression profiles and DNA methylation patterns showed some differences between patients with and without DNMT3A mutations. Notably, we found that members of HOXB genes were extensively upregulated with mutations of DNMT3A, and hypomethylation of certain CpG islands in the HOXB locus. DNMT3A mutations enabled 32D cells to acquire growth and survival advantage with and without IL3. Leukemias with DNMT3A mutations constituted a group of poor prognosis with elderly disease onset. These data suggest a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocytic leukemia and provides a useful new biomarker for relevant cases. We performed the study to systemically investigate the frequencies and the prognostic relevance of previously known genetic events and newly established molecular markers in a large series of 1,185 adult AML patients. In particular, we intent to stratify the AML patients who lacked cytogenetic prognostic markers into appropriate prognostic groups. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event free survival (EFS), while bi-allelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in whole group and younger patients aged less than 60 years. Further studies will be focused on using different treatment strategies according to AML genotypes.